DB0 Stock Overview

A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. More details

DB0 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue grew by 100% over the past year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 27.6% per year for the next 3 years

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Q32 Bio Inc. Competitors

4SC

DB:VSC

€27.3m

Heidelberg Pharma

XTRA:HPHA

€139.8m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€2.0m

Price History & Performance

Summary of share price highs, lows and changes for Q32 Bio
Historical stock prices
Current Share Price	US$1.32
52 Week High	US$46.40
52 Week Low	US$1.20
Beta	0
1 Month Change	10.00%
3 Month Change	-54.79%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-99.39%
Change since IPO	-99.49%

Recent updates

Shareholder Returns

	DB0	DE Biotechs	DE Market
7D	-15.4%	-0.01%	0.7%
1Y	n/a	-14.8%	12.8%

Return vs Industry: Insufficient data to determine how DB0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how DB0 performed against the German Market.

Price Volatility

Is DB0's price volatile compared to industry and market?
DB0 volatility
DB0 Average Weekly Movement	17.3%
Biotechs Industry Average Movement	6.1%
Market Average Movement	6.3%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: DB0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: DB0's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2017	43	Jodie Morrison	www.q32bio.com

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.

Q32 Bio Inc. Fundamentals Summary

How do Q32 Bio's earnings and revenue compare to its market cap?
DB0 fundamental statistics
Market cap	€16.83m
Earnings (TTM)	-€42.22m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is DB0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DB0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$48.14m
Gross Profit	-US$48.14m
Other Expenses	-US$410.00k
Earnings	-US$47.73m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-3.91
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	223.0%

How did DB0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/02 23:17
End of Day Share Price	2025/05/02 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Q32 Bio Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Thomas Smith	Leerink Partners LLC
Jay Olson	Oppenheimer & Co. Inc.
Christopher Raymond	Piper Sandler Companies